

# **Genome-wide association of multiple complex traits in outbred mice by ultra low-coverage sequencing**

Jérôme Nicod<sup>1</sup>, Robert W. Davies<sup>1</sup>, Na Cai<sup>1</sup>, Carl Hassett<sup>2</sup>, Leo Goodstadt<sup>1</sup>, Cormac Cosgrove<sup>3</sup>, Benjamin K Yee<sup>4</sup>, Vikte Lionikaite<sup>5</sup>, Rebecca E McIntyre<sup>6</sup>, Carol Ann Remme<sup>7</sup>, Elisabeth M. Lodder<sup>7</sup>, Jennifer S. Gregory<sup>5</sup>, Tertius Hough<sup>2</sup>, Russell Joynson<sup>2</sup>, Hayley Phelps<sup>2</sup>, Barbara Nell<sup>2</sup>, Clare Rowe<sup>2</sup>, Joe Wood<sup>2</sup>, Alison Walling<sup>2</sup>, Nasrin Bopp<sup>1</sup>, Amarjit Bhomra<sup>1</sup>, Polinka Hernandez-Pliego<sup>1</sup>, Jacques Callebert<sup>7</sup>, Richard M. Aspden<sup>5</sup>, Nick P Talbot<sup>9</sup>, Peter A Robbins<sup>9</sup>, Mark Harrison<sup>2</sup>, Martin Fray<sup>2</sup>, Jean-Marie Launay<sup>8</sup>, Yigal M. Pinto<sup>7</sup>, David A. Blizard<sup>10</sup>, Connie R. Bezzina<sup>7</sup>, David J Adams<sup>6</sup>, Paul Franken<sup>11</sup>, Tom Weaver<sup>2</sup>, Sara Wells<sup>2</sup>, Steve DM Brown<sup>12</sup>, Paul K Potter<sup>12</sup>, Paul Klenerman<sup>3</sup>, Arimantas Lionikas<sup>5</sup>, Richard Mott<sup>1, 13</sup> & Jonathan Flint<sup>1, 14</sup>

<sup>1</sup> Wellcome Trust Centre for Human Genetics, Oxford, United Kingdom

<sup>2</sup> Mary Lyon Centre, MRC Harwell, Harwell Science and Innovation Campus, United Kingdom

<sup>3</sup> Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

<sup>4</sup> Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hong Kong, China

<sup>5</sup> School of Medicine, Medical Sciences and Nutrition, College of Life Sciences and Medicine, University of Aberdeen, Aberdeen, Scotland, UK

<sup>6</sup> The Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK

<sup>7</sup> Heart Center, Department of Clinical and Experimental Cardiology, Academic Medical Center, Amsterdam, The Netherlands

<sup>8</sup> AP-HP, Hôpital Lariboisière, Department of Biochemistry, INSERM U942, Paris F-75475, France

<sup>9</sup> Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, U.K

<sup>10</sup> Department of Biobehavioral Health, Pennsylvania State University, University Park, PA 16802, USA

<sup>11</sup> Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland

<sup>12</sup> Mammalian Genetics Unit, MRC Harwell, Harwell Science and Innovation Campus, United Kingdom

<sup>13</sup> UCL Genetics Institute, University College London, London WC1E 6BT, UK

<sup>14</sup> Center for Neurobehavioral Genetics, Semel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, CA 90095

Correspondence should be addressed to J.F. ([JFlint@mednet.ucla.edu](mailto:JFlint@mednet.ucla.edu)) or R.M. ([r.mott@ucl.ac.uk](mailto:r.mott@ucl.ac.uk))

## **Contributions**

J.N. and J.F. designed the study and experiments. J.N., B.K.Y. and N.C. processed data. C.A., C.C., R.E.M., N.B., A.B., C.H., R.J., H.P., B.N., C.R. and T.H. phenotyped the mice and generated data. J.W. and A.W. developed bespoke LIMS and bioinformatics solutions for data collection, M.H. and M.F. managed importation and isolation procedures of mice into the MLC. S.W., T.W. and S.D.M.B. provided infrastructure, staff and established the phenotyping within the MLC. P.K.P. and J.N. managed the project. V.L., J.S.G. R.M.A. quantified bone size and mineral content. C.A.R., E.M.L., Y.P. and C.R.B. supervised cardiac data acquisition and analysed the cardiac data. J.C. and J-M.L. quantified serotonin. J.N., C.C., R.E.M., P.F., B.K.Y. and A.L. analysed the phenotypic data. N.C. and L.G. processed the sequencing data. R.W.D. and L.G. performed genotype imputation. R.M., J.N., N.C. and J.F. performed the genetic analysis. J.N., R.W.D., N.C., R.M. and J.F. wrote the manuscript with input from co-authors.

## **Competing financial interests**

The authors declare no competing financial interests.

## **Acknowledgments**

We thank the High-Throughput Genomics Group at the Wellcome Trust Centre for Human Genetics and the Wellcome Trust Sanger Institute for the generation of the sequencing data. This work was funded by Wellcome Trust grant 090532/Z/09/Z (J.F.). Primary phenotyping of the mice was supported by the Mary Lyon Centre and Mammalian Genetics Unit (Medical Research Council, UK Hub grant G0900747 91070 and Medical Research Council, UK grant MC U142684172). D.A.B acknowledges support from NIH R01AR056280. The sleep work was supported by the state of Vaud (Switzerland) and the Swiss National Science Foundation (SNF 14694 and 136201 to P.F.). The ECG work was supported by the Netherlands CardioVascular Research Initiative (Dutch Heart Foundation, Dutch Federation of University Medical Centres, the Netherlands Organization for Health Research and Development, and the Royal Netherlands Academy of Sciences) PREDICT project, InterUniversity Cardiology Institute of the Netherlands (ICIN; 061.02; C.A.R., C.R.B). Na Cai is supported by the Agency of Science, Technology and Research (A\*STAR) Graduate Academy. The authors wish to acknowledge excellent technical assistance from: Ayako Kurioka, Leo Swadling, Catherine de Lara, James Ussher, Rachel Townsend, Sima Lionikaite, Ausra S. Lionikiene, Rianne Wolswinkel and Inge van der Made. We would like to thank Thomas M Keane and Anthony G Doran for their help in annotating variants and adding the FVB/NJ strain to the Mouse Genomes Project.

## Abstract

Two bottlenecks that have impeded the genetic analysis of complex traits in inbred strain crosses and populations derived from them, are the lack of gene level mapping resolution and the need for population specific genotyping arrays and haplotype reference panels. To address these problems we mapped multiple complex traits at high resolution in a highly recombinant commercially-available outbred mouse population, using imputed genotypes from 0.15x whole genome sequencing. By simultaneously imputing the ancestral haplotype space comprising 5,766,828 single nucleotide polymorphisms and the genomes of the mapping population at 359,559 tagging variants, we mapped 255 quantitative trait loci representing 156 unique regions in 1,887 mice for 92 phenotypes. Linkage disequilibrium decays fast enough to provide gene-level mapping resolution at about a fifth of loci. Our results implicate *Unc13c* and *Pgc1-alpha* at loci affecting the quality of sleep, *Adarb2* for home cage activity, *Rtkn2* for intensity of reaction to startle, *Bmp2* for wound healing, *Il15* and *Id2* for several T-cell measures and *Prkca* for bone mineral content. Six diverse phenotypes map over the *Met* gene: muscle weight, startle response, serum albumin, calcium, protein and cholesterol levels, suggesting this is an important pleiotropic locus. These findings have implications for diverse areas of mammalian biology and demonstrate how GWAS can be extended via low-coverage sequencing to species with large highly recombinant outbred populations.

## Introduction

Genome-wide association studies (GWAS) have delivered new insights into the biology and genetic architecture of complex traits but so far they have found application primarily in human genetics<sup>1,2</sup> and in plant species where naturally-occurring inbred lines exist<sup>3,4</sup>. Two obstacles stand in the way of their routine application in other species: access to a mapping population able to deliver gene-level mapping resolution, and the deployment of a genotyping technology able to capture at least the majority of those sequence variants that contribute to phenotypic variation, in the absence of haplotype reference panels of the kind routinely employed in human populations to impute sequence variants.

In this study we exploit the properties of commercially available outbred mice for GWAS in the Crl:CFW(SW)-US\_P08 stock. Compared to other mouse mapping populations, commercial outbred mice are maintained at relatively large effective population sizes and are descended from a relatively small number of founders, with mean minor allele frequencies and linkage disequilibrium (LD) resembling to those found in genetically isolated human populations<sup>5</sup>. While LD extends over a larger range than in general human populations, such populations can still deliver gene level resolution<sup>5</sup>. Furthermore, compared to a human GWAS, comparatively fewer markers are needed to tag the genome, thus requiring a lower significance threshold and smaller sample sizes than are usual for a human GWAS.

GWAS methodology typically uses arrays to genotype known Single Nucleotide Polymorphisms (SNPs) and hence represent each individual's genome as a haplotype mosaic of a reference panel of more densely typed or sequenced individuals (such as the 1000 Genomes project<sup>6</sup>), to impute genotypes at the majority of segregating sites in a

population <sup>7</sup>. However, in common with other populations that have not previously been subject to GWAS, commercial outbred mice lack accurate catalogs of sequence variants, allele frequencies and haplotypes, thus excluding the application of standard GWAS approaches.

We show here how low coverage sequencing overcomes these limitations. We apply a method that models each chromosome as a mosaic of unknown ancestral haplotypes that are jointly estimated as part of the analysis, exploiting phase information in sequence reads to optimize haplotype reconstruction. Using this approach we map the genetic basis of multiple phenotypes in almost 2000 mice, in some cases at near single-gene resolution, thereby providing insights into the biology of a number of bio-medically important traits.

## **Results**

### *Phenotypes*

For this experiment we chose the Crl:CFW(SW)-US\_P08 outbred stock (CFW) from Charles River, Portage, USA <sup>5</sup> and subjected 2,049 adult mice to a four-week phenotyping pipeline (see Methods and Supplementary Figure 1). The phenotype battery is notable for both the depth of information provided (anatomical, biochemical, immunological, physiological and behavioral measures) as well as the assessment of phenotypes rarely mapped in mice. The latter include assessments of sleep and cardiac electrical function (electrocardiography). We provide measures for 200 phenotypes from 18 assays (Methods), for each of which data are available on a mean of 1,578 animals (range 905 - 1,968). We assign each measure to one of the following three heuristic categories:

behavior, physiological or tissue; physiological measures include those taken when the mice were alive such as body weight and cardiac function, while the tissue measures comprise those obtained after dissection such as blood clinical chemistry and neurogenesis. Supplementary Table 1 lists the phenotypes reported here, the category to which they belong, the means and standard deviations on all animals and also separately for each sex. For 63% of the measures males and females are significantly different at  $P < 0.05$ . We tested the effect of all potential covariates on the variance of each measure in order to regress them for the genetic analysis. The strongest effect comes from the batch, affecting 190 measures with a mean effect of 15%. This is unsurprising as batch is confounded with many environmental factors including shipment, time of year or experimental day.

### *Genotypes*

In order to capture all common variants in the CFW mice, we employed a two-stage genotyping strategy using low coverage sequencing that makes use of, but does not require, prior knowledge of segregating sites. We first generated a list of candidate variant sites using GATK<sup>8</sup> and then imputed genotype probabilities at these sites.

We obtained a mean coverage of 0.15X sequence coverage per animal for 2,073 mice (range 0.06X to 0.51X). We identified 7,073,398 single-nucleotide polymorphisms (SNPs) in the ~370X pile-up of all sequence data that segregated in our sample and were either polymorphic in laboratory strains sequenced in the mouse genomes project (MGP) (3), or passed GATK's variant quality score recalibration (VQSR) (Methods). We then imputed genotype dosages at these sites using our reference-panel free method, STITCH (Methods, and described in Davies *et al* 2016). After stringent post-imputation

quality control we retained 5,766,828 high-quality imputed SNPs for subsequent analysis. Accuracy at these sites is very high: the mean SNP-wise correlation ( $r^2$ ) against sites polymorphic on a genotyping microarray<sup>9</sup> using 44 samples was 0.974 before QC and 0.981 after QC. We annotated the high-quality imputed SNPs using the mouse reference mm10 assembly and identified 11,931 SNP positions in protein coding sequence that lead to amino acid changes in 3,938 individual genes (non-synonymous substitutions) and 25,669 that do not (synonymous substitutions). Supplementary Table 2 lists the variants per chromosomes and Supplementary Table 3 lists the number of variants obtained at each stage of the variant calling and imputation process.

### *Genetic architecture*

Inspection of the genetic variation segregating in CFW mice revealed several notable characteristics. The total of 5.7 million variants in the CFW mice is about 1/3 fewer than the number segregating in crosses derived from classical laboratory inbred strains (heterogeneous stocks<sup>10, 11</sup>, Hybrid Mouse Diversity Panel, HMDP<sup>12</sup>) but far less than the 45 million segregating in the recently created Collaborative Cross (CC) and Diversity Outbred (DO) populations using wild-derived strains from different subspecies of mice<sup>11</sup>.

The distribution of variants across the genome was highly non-uniform (Figure 1A). Chromosome 16 has only 20% of the variants found on chromosome 15, despite being almost the same size (Supplementary Table 2). This likely reflects an extreme bottleneck in the founding of the CFW, a view supported by the fact that only four ancestral haplotypes were required for the imputation procedure to work effectively. On chromosome 19, on average, at each SNP 87.1% of samples are represented by only two haplotypes.

Rates of heterozygosity are low (Figure 1B) with 22% of the genome close to fixation (Figures 1A and 1C). Of the 5.7M imputed variants, 97.6% were found in 36 sequenced inbred strains in the Sanger Mouse Genomes database Release 1505. The FVB/NJ strain alone contributes 38% of non-reference CFW alleles (Supplementary Table 4) and in combination with the progenitors of the mouse HS<sup>45</sup> account for 76%. Wild-derived strains (LEWES/EiJ, ZALENDE/EiJ, WSB/EiJ, CAST/EiJ, MOLF/EiJ, PWK/PhJ, SPRET/EiJ) only account for about 5% of alternative alleles absent from other sequenced strains.<sup>11,13</sup> Both novel and known variants have very similar minor allele frequency distributions across the genome (Figures 1C and 1D). Average minor allele frequency (MAF) was 0.19, with 18.4% of variants having MAF <0.05. Figure 1E shows the decay of linkage disequilibrium with increasing distance (providing an indication of the expected mapping resolution obtainable with the CFW mice). Average pairwise  $r^2$  falls to 0.28 at 1Mbp, 0.16 at 2 Mbp, and 0.10 at 3 Mbp. We identified a subset of 359,559 SNPs, that tag all other SNPs with MAF >0.1% at LD  $r^2$ >0.98. This subset was used for subsequent analyses except where stated otherwise.

To investigate population structure and unequal relatedness between the 2073 mice, we estimated identity by descent (IBD) from allele sharing between tagging SNPs (Methods); Supplementary Figure 2 plots the proportion of genome with IBD = 1 against IBD = 0. For GWAS, we removed 135 animals with higher relatedness than second-degree relatives, and 4 outliers identified from principal component analysis (PCA) on a genetic relatedness matrix (GRM, Methods). The population structure of the remaining 1934 animals was further assessed by performing another PCA on a GRM from only these mice; Supplementary Figure 3 plots the relationship between the first 5 principal components and shows no evidence of extensive structure.

### *Genome-wide association*

Genotypes and phenotypes were available for 1887 mice. We performed GWAS by testing association between the 359,559 tagging SNPs and all phenotypes. We first transformed each phenotype by regression on relevant covariates (see Methods) and quantile-normalised the residuals. We used a genetic relationship matrix (GRM) in a mixed linear model to control for population structure and genetic relationship. To test for association with SNPs on a given chromosome, we used a GRM based on those tagging SNPs on the other chromosomes<sup>14,15</sup> to increase power<sup>16</sup>. We calculated a genome-wide false discovery rate (FDR) separately for each phenotype, using permutations of the mixed model-transformed phenotypes to determine empirical trait-specific genome-wide significance thresholds (Methods).

At a 5% FDR, we identified 255 QTLs in 92 out of 200 phenotypes (46%), as shown in Supplementary Table 5. Quantile-quantile plots for a representative selection of phenotypes are given in Supplementary Figure 4. It should be noted that due to the large number of SNPs used (in this case not pruned for LD) and the fact that LD extends over longer distances than exist in human populations, deviation from the expected values extends over a larger range of P-values than is commonly seen in quantile-quantile plots generated for human association studies.); plots of all QTLs are available at <http://outbredmice.org>). Statistical power is expected to increase with MAF, and in our QTLs the MAF of significantly associated SNPs (range 1.7-50%, median 31%) was higher than expected (compared to all 5.7M SNPs) (Mann Whitney U test,  $P = 1.95e-28$ ): 133 QTLs (52%) have a  $MAF > 30\%$  and only 11 (4%) below 5% (Figure 2a). Among the 5.7M imputed SNPs, 25% have  $MAF > 30\%$  and 18%  $MAF < 5\%$  (Figure 1c).

To aid gene identification, we estimated the 95% confidence intervals (CI) of every QTL using a method based on the LOD-drop concept<sup>17</sup>. To do so, around each QTL we simulated causal SNPs that matched the QTL's observed effect size. A local scan of the region using the same mixed model but using a simulated phenotype was performed, and the location and LogP of the top SNP recorded. From 1,000 simulations, we derive a distribution of the drop ( $\Delta$ ) in LogP between the most highly associated SNP and the causal SNP ( $\Delta$  is zero when the top and causal SNPs coincide). Since the width of the interval containing  $\Delta$  is well-calibrated with respect to true confidence intervals<sup>17</sup>, the fraction of simulations  $f(\Delta)$  within  $\Delta$  can be used to determine confidence intervals for the original phenotype data<sup>17</sup>. The 95% CIs ranged from 0.01-7.33Mb with a mean at 1.50Mb; 43% of QTLs being less than 1Mb in size. On average each QTL covered 19 protein coding genes (0-205) with a median of 9 genes. Figure 2b shows the distribution of the number of genes at a QTL. Mapping results can be visualised at <http://mus.well.ox.ac.uk/gscandb/> (GScanViewer)<sup>18</sup> and at <http://outbredmice.org>.

### *Heritability and variance attributable to QTLs*

SNP-based heritability estimates,  $h^2$ , based on a GRM computed from the tagging SNPs, were greater than 0 (at  $P < 0.05$ ) for 152 of 200 phenotypes, with a mean value of 26.3%, (range 9.1-71.1%), as reported in Supplementary Table 1. To assess how much of the heritability can be explained by detected QTLs (FDR < 5%), we first estimated the effect size of each QTL by performing analysis of variance (ANOVA) at the most significantly associated SNP then summed the variance explained by all QTLs associated with every phenotype. On average, 21.1% of the heritability estimated for each trait with significant  $h^2$  estimates can be explained in this way (Figure 2c). This indicates that missing

heritability affects the CFW population, although to a lesser degree than most human GWAS.

Traits with higher heritabilities yielded more QTLs than traits with lower heritabilities: the mean heritability of those traits for which at least one QTL was identified was 30.6%, compared to a mean heritability of 20.6% for those traits for which no QTLs were detected, a highly significant difference (t-test P-value =  $8.9 \times 10^{-8}$ ). Mean heritabilities differed between the three categories of phenotypes: 14.5% for behavior, 18.2% for physiological and 24.2% for tissue phenotypes. We also noted the same pattern in the median locus effect size of the three categories: 1.37% for behavioural QTLs, 1.5% for physiological and 2.8% for tissue QTLs (Figure 2c).

#### *Distribution of QTLs reflects genetic diversity along the genome*

Many of the loci detected overlap, and are associated with, closely related phenotypic measures. Examples include the 2 QTLs for HDL and total cholesterol mapping over the *Apoa2* gene on chromosome 1<sup>19</sup>, or the 8 different bone mineral content measures mapping over *Slc4a2* on chromosome 5<sup>20</sup>. To avoid redundancy in our analysis we considered that if two overlapping QTLs (where the top SNP of the first QTL lies inside the 95% CI of the second QTL) were associated with measures of the same biological function they were representing a unique locus. Using this approach we identified a reduced set of 156 unique loci, each associated with 1 to 12 measures. We report these 156 unique QTLs in Supplementary Table 6 with all the measures associated with each locus. A “porcupine” plot on Figure 3 shows the superimposed Manhattan plots of all the measures where a least one QTL was detected and highlights the 156 unique loci. Some regions of the genome are devoid of any QTLs, reflecting the uneven genomic

distribution of sequence variants, a prime example being the lack of any QTL detected on chromosome 16 (Figure 1A). Figure 3 also highlights the presence of clusters of QTLs, notably on chromosomes 6, 11, 17 and X. The chromosome 17 locus overlaps the major histocompatibility complex (MHC), a naturally highly polymorphic region in wild populations that remains highly variable in the CFW mice.

### *High-resolution QTLs confirm known genetic associations and identify novel candidate genes*

We focused on those QTLs containing small numbers of genes, since these loci provide a starting point for functional investigation of the relevant phenotypes. Of the 156 unique loci identified in this study, 56 contain three or fewer genes (36%) and 25 contain a single gene in the 95% confidence interval (6 QTLs do not overlap any gene).

Table 1 lists the 25 QTLs containing a single gene. The table categorizes QTLs into three classes, according to prior evidence supporting the candidacy of the gene at the locus. (i) Phenotypes of knockouts support candidacy of three genes: *Met*, *Fli1*, and *Grm7*. The locus on chromosome 6 containing the *Met* gene contributes to all five muscles weight measures (Figure 4a). *Met* encodes a hepatocyte growth factor receptor and has a known function in embryonic development<sup>21,22</sup> and regeneration<sup>23</sup> of adult limb skeletal muscle. *Fli1* modulates B cells development<sup>24</sup> and mice lacking *Grm7* are more active when placed in a novel environment<sup>25</sup> (ii) The genes at six loci are strongly corroborated by prior published evidence. These include the bone morphogenetic protein *Bmp2* at a locus for wound healing<sup>26</sup>; PGC-1 $\alpha$ , at a locus for sleep fragmentation, is involved in regulating inhibitory neurotransmission in the cerebral cortex associated with cortical hyperexcitability<sup>27</sup>; a protein kinase (PKC $\alpha$ ) that promotes osteoblastic cell

proliferation, at a locus for bone mineral content <sup>28,29</sup>; the pre B cell leukemia homeobox 1 (*Pbx1*) at a locus influencing NK cells population <sup>30</sup> and finally an Interleukin (Il15, Fig 4d) <sup>31</sup> and the transcription factor *Id2* <sup>32</sup> at two independent loci affecting several T-cell measures. (iii) The remaining 16 QTLs contain single genes not previously associated with the trait, including 5 that concern behaviour. Notably, our mapping results implicate *Unc13c* in the quality of sleep (duration of long bouts of sleep, Fig 4b). UNC13C is involved in synaptic transmission <sup>33</sup>, but has never previously been associated with sleep. However, there is evidence for the differential expression of the human ortholog in individuals with poor sleep quality<sup>34</sup>. Basal home cage activity is associated with *Adarb2*, a brain-specific adenosine deaminase acting on RNA <sup>35,36</sup>. *Rtkn2*, a member of the rhotekin family predominantly expressed in lymphoid cells <sup>37</sup>, influences intensity of reaction to startle (Fig 4d). CNVs for the human orthologue of *Rtkn2* have been implicated in attention-deficit and hyperactivity disorder <sup>38</sup>. Similarly, the QTL for hypoxic ventilatory depression maps to the *Hcn1* gene encoding a hyperpolarization-activated cyclic nucleotide-gated cation channel.

The low-coverage population-based sequencing approach used in this study provides a near complete catalogue of the SNPs segregating in our population, most importantly identifying SNPs that would have been ignored using microarrays for genotyping. We could also test associations at candidate variants responsible for the effect. The *Met* gene on chromosome 6 is associated with muscle phenotypes and our sequence data revealed two missense variants: I851M and R968C. The first variant is common amongst mouse inbred strains and is not known to alter gene function. The second variant, confirmed by Sanger sequencing, is specific to the SWR/J strain <sup>39</sup>. The human homolog (R988C) has been identified in two small cell lung cancer cell-lines and

increases constitutive tyrosine phosphorylation activity *in vitro* <sup>40</sup>. The R968C missense variant is highly associated with the five muscle weight phenotypes but the direction of the effect of the alternative allele is positive in extensor digitorum longus (EDL) and gastrocnemius and negative in the others. This difference reflects differences in the muscle fiber composition (soleus is dominated by type 1 and 2A fibers, EDL is enriched in 2X and 2B fibers <sup>41</sup>) suggesting that R968C affects these fibers differently or shifts the composition in all muscles.

## Discussion

Genome-wide association mapping for complex traits has been used extensively in human populations but less commonly in outbred populations of other organisms. We have shown here that mapping using commercially available outbred mice can identify individual genes involved in complex traits, some of which cannot easily be assayed in human subjects. Our results raise issues about the nature of mouse resources for mapping complex traits, and about the biological insights that can thereby be attained.

Several resources have been developed to provide GWAS tools to rodent genetics. These resources fall into two broad categories: (i) genetic reference populations, consisting of pre-existing inbred strains (Hybrid Mouse Diversity Panel, HMDP <sup>12</sup>) or recombinant inbred strains (BxD<sup>42</sup> and Collaborative Cross<sup>43</sup>), (ii) populations descended after multiple generations of pseudo-random breeding from inbred strains (diversity outcross (DO) mice <sup>44</sup> and heterogeneous stocks (HS)<sup>45</sup>). Each resource differs in its utility for GWAS, and no single population is ideal <sup>1</sup>.

Commercially available outbred mice are an alternative resource with a number of advantages, and the CFW stock has already been used to map skull shape QTLs <sup>46</sup>.

Compared to HMDP and HS animals, there was minimal evidence for population structure, and standard GWAS methods developed for human populations can be applied. LD decays fast enough to provide gene-level mapping resolution at about a fifth of loci, and although the resolution is still lower than in human populations, it is better than other mouse resources. The size of QTLs varied considerably, with the largest ones extending over several megabases, but half contained less than 10 genes, providing a relatively small list to investigate the biology at these sites.

Compared to other rodent mapping resources, our results also indicate that the CFW population delivers fewer loci for fewer phenotypes. We mapped loci for 92 out of 200 traits included in our phenotyping pipeline, yielding a mean number of 1.3 QTLs per trait, in 1,887 mice. One possible explanation for the low yield of QTLs is that the amount of genetic variation present in the CFW stock is relatively limited. Indeed, almost a quarter of the CFW genome is virtually devoid of variants (including almost all of chromosome 16). For comparison, the 5.7M variants in the CFW is less than the 7.2M segregating in the rat heterogeneous stock <sup>10</sup>. However, a more important determinant for QTL detection in the CFW is likely to be allele frequencies ( $p$ ), which are on average lower in the CFW than in the HS. Since the variance explained by a QTL is proportional to  $p(1 - p)$ , effect sizes, and hence power, are systematically smaller in the CFW. Indeed, the median effect size is 1.6%, which, while dwarfing the effects found to underlie human quantitative traits, is still less than half that found in the rat HS (median estimate 5%) <sup>10</sup>. Supplementary Table 7 summarises the expected power to detect QTLs in the CFW population.

The inclusion of a large number of behavioural measures in our pipeline also contributed to the relatively low QTL detection rate. Almost a third of the traits

(63/200) were collected from behavioral tests, yet the QTLs mapped with these measures accounted for less than 14% of the total. These phenotypes typically had lower heritabilities, with fully one quarter (16) having no significant genetic contribution. It should be noted that these non-significant estimates (as well as those for non-behavioural phenotypes) do not necessarily mean the traits are not heritable: as shown in Supplementary Table 1, the standard errors on these estimates are large, so that no heritability less than 10% can be reliably estimated. Those loci we did detect had lower effect sizes (mean for behavioural QTLs was 1.37, compared to 1.5 for physiological and 2.8 for tissue QTLs).

The heritability of the behavioural measures might also have been affected by the fact that mice were repeatedly tested over a 4 weeks period. Most behaviors are sensitive to repeated handling and repeated exposure to different types of novel stimuli, as will happen during the extensive phenotypic battery deployed here. Habituation to these exposures makes it harder to detect alleles that affect baseline differences in behavior, especially anxiety-like behaviors for which three different assays were conducted over a relatively short time frame. A more focused assessment of a specific behavioral phenotype under tightly controlled environmental conditions could have yielded higher heritabilities for some traits.

These observations lead to two conclusions. First, finding more QTLs in the CFW will require thousands of mice. Supplementary Table 6 gives the power to detect QTLs in the CFW population as a function of effect size and sample size. For a typical QTL corresponding to the median effect size (1.6%) and sample size (1,732) in the current study, power is about 80% at a genomewide significance level of 10%. Power falls off for smaller effects sizes. Thus a 0.5% QTL is detectable at only 6.6% power with 1,732

animals; increasing the sample size to 4,000 increases the power to 51%, and with 6,000 it is 85%. However, “winner’s curse” means that the true effects are likely to be lower than reported here, and given that our QTLs explain only 20% of the heritability it is reasonable to assume that the majority of loci will have effect sizes less than 1%. Second, additional loci can be found using different stocks. Not all commercial outbred mice populations are the same, as we previously documented in a survey of 66 stocks in which mean heterozygosity varied from 0.5% to 45% and mean minor allele frequencies from 0.03% to 0.5%<sup>5</sup>. The use of complementary populations will make additional alleles open to discovery.

Our study is the first to use extremely low coverage sequence to generate accurate genotypes without a reference panel. This strategy is generally applicable to any population, and any species, for which there is no information about segregating variation or haplotypes. It is competitive with arrays in terms of cost, although the optimal choice of strategy will depend on the reagents available for the population in question. An advantage of sequencing over array-based genotyping is that it does not require prior information about which variants are segregating in a population; nor does it require a pre-existing catalogue of variants or prior knowledge of the likely founders of the population.

One unexpected finding was that, only 25,000 SNPs in the standard megaMUGA mouse genotyping array are polymorphic in the CFW mice; many of the QTLs we mapped would likely have been overlooked by genotyping with this array. The CFW mice appear to be descended from four ancestral haplotypes, indicating this population was likely bottle-necked to two founding individuals. Our population is effectively bi-

allelic at most loci, and there was little to be gained by considering haplotype-based tests of association (data not shown).

We have shown here how commercially available outbred mice can deliver novel biological insights. We found single genes at 16 loci where no prior evidence existed for their involvement (Table 1). Importantly, the loci include those from phenotypes that could not easily be assayed in human subjects, such as response to hypoxia and the sleep phenotypes. More than 50 QTLs contain documented candidate genes (Supplementary Table 5): *Slc4a2*, which leads to osteopetrosis when disrupted in mice <sup>20</sup>, is present at a QTL affecting bone mineral content; *Apoa2* and *Scarb1*, both known to affect blood lipid homeostasis <sup>19,47</sup> are detected at two distinct QTLs for cholesterol levels; *Gdnf*, a gene required for the neuronal colonization of the pancreas, at a locus for pancreatic amylase <sup>48</sup>. These examples demonstrate that the narrow QTLs detected in the commercially available outbred mice can lead to the identification of the genes affecting the measured traits, emphasizing the potential of our results as a resource to identify new genes in those QTLs without documented candidates.

## Methods

### *Study animals and phenotyping*

A total of 2117 outbred mice (Crl:CFW(SW)-US\_P08, 1065 males and 1052 females) were purchased from Charles River, Portage, USA at 4-7 weeks of age over a period of 2 years. Animals were selected from the breeding colony as to avoid siblings and half-siblings. Monthly shipments of approximately 130 mice were delivered, maintained and tested at the MRC Harwell in Harwell, Oxfordshire, UK following local regulations. Mice of the same age within each shipment were treated as a batch (approximately 30 animals, range 7 to 36, half males and half females, the total number of batch for the entire study is 69) and each animal randomly assigned a testing order. Mice were housed in IVC cages (3 per cage) on an *ad lib* diet for the duration of the study. At 16 weeks of age 2049 mice started a 4-weeks phenotyping pipeline in which we collected behavioral and physiological data (Suppl. Fig. 1). Mice within a batch performed each test during the same day following the assigned testing order. The sequencing of the animals was performed after completion of the study so experimenters were blind to the genotype of the mice during testing. Power calculations to estimate the sample size for the mapping experiment assumed effect sizes were similar to those identified in a previous analysis of outbred stocks<sup>5</sup>. Every effort was made to minimize suffering by considerate housing and husbandry. All phenotyping procedures were examined for potential refinements. All animal work was carried out in accordance with UK Home Office regulations. The project was reviewed by the ethics committee at MRC-Harwell: Animal Welfare and Ethical Review Board, approval license PPL 30/2653.

## *Behavior*

Anxiety was modeled by 3 tests: Five minutes activity in a bright lit round arena (Open Field Test), Elevated Plus Maze and latency to eat a novel food after 10 hours food restriction (Neophagia). We also measured home cage activity over a 30 minutes period using photoactivity system from San Diego Instruments (San Diego, CA). Protocols for these tests have been described in <sup>49</sup>. Pre-pulse inhibition of startle (Startle PPI) was measured and analyzed as previously described, using 3 different pulse and 3 different prepulse intensities <sup>50,51</sup>. Fear conditioning was performed following the protocol in <sup>52</sup>, keeping the order of context and cue testing sessions identical for all mice. On the first day of the test mice were subjected to a 13 minutes training session during which they were placed in a Perspex enclosure with a metal grid floor and received 2 electric foot shocks (0.3mA, 0.5sec) preceded by a 30 seconds tone. In the morning of the second day of the test the mice were placed in the same enclosure for 5 minutes and fear associated with the context was measured by the amount of freezing. In the afternoon the animals were placed in a different enclosure for 5 minutes where they were subjected to two 30 seconds tones without any paired electric shock. The fear associated to the cue was assessed by measuring the freezing behaviour during tones. Freezing behaviour during all sessions of the test was scored using a VideoTrack automated system (Viewpoint, Champagne Au Mont D'Or, France). Because the distribution of the measures varied significantly between the 4 enclosures in which the mice where tested for fear conditioning, we quantile normalised the data per enclosure before performing further analysis. Depressive-like behavior of mice was assessed with the forced swim test <sup>53</sup>. Animals were placed for 6 minutes in a 30cm diameter plastic cylinder filed with water

at 25°C. Immobility of the mice during the last 4 minutes was scored using VideoTrack FST automated system (Viewpoint, Champagne Au Mont D'Or, France).

#### *Ventilatory responses to acute hypoxia*

Ventilatory responses to acute hypoxia were measured using whole body plethysmography. Awake unrestrained mice were placed in individual plethysmographs (550 ml volume, Model PLY3211, Buxco, Wilmington, NC USA) to which premixed gases were delivered at a rate of 2 L min<sup>-1</sup>. After a brief (5-min) acclimatisation period, mice were exposed to 15 min of 21% O<sub>2</sub>, balance N<sub>2</sub> (pre-normoxia), followed by 5 min of 10% O<sub>2</sub>, balance N<sub>2</sub> (hypoxia), followed by a final 5-min period of 21% O<sub>2</sub> (post-normoxia). Tidal volume (TV) and respiratory frequency (f) were measured continuously, and used to calculate minute ventilation (MV). For each of these three parameters, the following indices of the respiratory phenotype were derived: *i*) Baseline (mean value for MV, TV or *f* during the final 3 min of pre-normoxia); *ii*) Acute Hypoxic Response (AHR, difference between the mean value during first 30 sec of hypoxia and the Baseline); *iii*) Hypoxic Ventilatory Decline (HVD, difference between mean value during the first 30 sec of hypoxia and mean value during final 2 min of hypoxia); *iv*) Undershoot (difference between mean value during the first 30 sec of post-normoxia and the Baseline); *v*) Off-Response (difference between mean value during first 30 sec of post-normoxia and mean value during final 2 min of hypoxia); *vi*) Sustained Hypoxia Response (SHR, difference between Off-Response and Undershoot); and *vii*) Normoxic Recovery (NR, difference between value during first 30 sec of post-normoxia and final 2 min of post-normoxia).

#### *Electrocardiography*

For surface electrocardiography (ECG), mice were anesthetized using isoflurane inhalation (induction: 4.0 volume % in oxygen; maintenance: 1.5-2.5 volume %). Surface ECGs were recorded from subcutaneous 23-gauge needle electrodes attached to each limb using the Powerlab acquisition system (ADInstruments). ECG traces were signal averaged and analysed for heart rate (RR interval), PRmain (interval between start P wave and start QRS complex), PRpeak (interval between start P wave and R peak), QRSmian (interval between start of QRS complex and S peak), QRSpik (interval between R peak and S peak), QTmain (interval between start of QRS complex and end of T wave), and QTpeak (interval between R peak and end of T wave) using the LabChart7Pro software (ADInstruments). QTmain and QTpeak intervals were corrected for heart rate using the formula:  $QTc = QT / (RR/100)^{1/2}$  (RR in ms).

### *Sleep*

At the end of the phenotyping pipeline mice were moved to individual cages to assess their baseline sleeping behaviour using a non-invasive EEG-validated piezo-electric sleep recording system <sup>54</sup> (MouseRec system by Signal Solutions, LLC, Lexington, KY, USA). Sleep was recorded for 72 hours but only the last 48 hours were used for analysis thus allowing one day of habituation. Light-dark cycle (12h:12h light:dark) and ambient temperature (21°C) during the recordings were the same as in the colony rooms. In each of the 1607 mice for which good quality signals could be obtained, 19 sleep phenotypes were quantified concerning the amount of sleep, its distribution over the 24h day, and the fine structure of sleep (e.g. sleep bout duration and sleep fragmentation). All values are reported per 24h and represent the average over the last two 24h recording periods starting at light onset.

### *Body weight*

We measured body weight at 17, 18, 19 and 20 weeks of age. The last measure was collected immediately before sacrifice after overnight fast. We calculated Body Mass Index (BMI) by dividing the body weight at 20 weeks by the square of the body length, collected at the same time. We also calculated a “pseudo BMI” dividing the body weight at 20 weeks by the square of the length of the tibia.

At 20 weeks of age mice were sacrificed between 8am and 12pm after overnight food restriction and tissues harvested for further measures. We measured body and tail length during the procedure.

### *Haematology*

Whole blood samples for haematology were collected by cardiac puncture into 200µl EDTA coated paediatric tubes. Samples were placed on a rotary mixer for 30 minutes before full blood count and differential analyses were performed on board a Siemens Advia 2120 haematology analyser.

### *Clinical Chemistry*

Blood samples were collected by cardiac puncture into 1ml lithium heparin-coated paediatric tubes. Samples were mixed by gentle inversion and centrifuged within 2 hours of collection at 5000 X g, for 10 minutes in a refrigerated centrifuge set at 8°C. 200µl of plasma was collected from each sample and analysed on board a Beckman Coulter AU680 clinical chemistry analyser using reagents and settings as recommended by the manufacturer for the following profile of 20 tests: sodium, potassium, chloride, urea, creatinine, total calcium, inorganic phosphorous, alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase

(LDH), total protein, albumin, total cholesterol, HDL cholesterol, LDL cholesterol, glucose, triglycerides, glycerol, free fatty acids, total bilirubin, iron and alpha amylase.

#### *Platelet serotonin*

A small aliquot of whole blood was immediately snap frozen after collection by cardiac puncture into a lithium heparin-coated tube. At the time of measure 10µl of this whole blood aliquot was thawed and used for serotonin quantification. Serotonin was extracted by adding 390 µl of 10<sup>-3</sup> M HCl containing sodium metabisulfite, EDTA and ascorbic acid. After 30 sec shaking, samples were centrifuged at 20000g for 20 min at 5°C. The supernatants were collected and filtered through a 10 kDa membrane (Nanosep, Pall) by centrifugation at 7000g. Then, a 20 µl aliquot was analysed for serotonin by fluorometric detection <sup>55</sup>.

#### *Micronucleus*

We measured the formation of micronuclei, markers of genomic stability, in erythrocytes by flow cytometry <sup>56</sup>.

#### *Neurogenesis*

Following sacrifice the brain was weighted and then split in two halves by sagittal section and the left hemisphere fixed overnight in 4% paraformaldehyde followed by dehydration in 30% sucrose solution for 3-5 days. Sections (40 µm) were prepared on a freezing microtome and stored in antifreeze solution at -20°C. We measured hippocampal neurogenesis by Ki67 and DCX staining <sup>57</sup>, counting labelled cells on every sixteenth (DCX) or eighth (Ki67) section through the entire rostrocaudal extent of the granule cell layer.

### *Wound healing*

We measured healing of hole punctures made to the animal's ears following the approach described in <sup>58</sup>. A 2-mm diameter hole was made in the center of each ear when the mice started the phenotyping pipeline (16 weeks old) and following sacrifice 5 weeks later ears were fixed and stored in 4% paraformaldehyde. Both ears were then flattened between 2 coverslips, scanned at 600dpi and the image analysed with the ImageJ software to measure the area of the hole still open. We excluded ears when the hole merged with the edge of the ear and only analysed mice when both ear measures were available.

### *Adrenal weight*

Following sacrifice adrenals were removed together with the kidneys, fixed and stored in 4% paraformaldehyde. Adrenals were dissected from the kidneys at a later day and their weight measured. Data was analysed only when weight from both adrenals was available.

### *Immunology*

Following sacrifice, mouse spleens were stored in PBS on ice prior to processing. Splenocytes were extracted by mashing the spleen through a 45µm filter using the plunger end of a syringe. The cells were then washed extensively with PBS and re-filtered prior to staining. Erythrocyte contamination in the splenocyte sample was minimal. Splenocytes were stained with fixable near-IR dead cell stain (Life Technologies), CD3e PE Cy7, CD45 V450, CD44 FITC, CD4 V500 (all BD Bioscience), CD49b APC, CD19 PE, CD8a PerCP Cy5.5 (all eBioscience) for 25 minutes in the dark at

4°C before being fixed in 2% formaldehyde solution. Data were collected using a 3-laser LSRII or MACSQuant flow cytometer and analysed on Flowjo v8.4 (Treestar, OR, USA).

#### *Muscle weight and tibia length*

Following sacrifice, one hindlimb was removed and transferred to a -70 °C freezer. On the day of dissection, the leg was defrosted and two dorsiflexors (tibialis anterior (TA), and extensor digitorum longus (EDL)), and three plantar flexors (gastrocnemius (“gastroc”), plantaris and soleus) were dissected under a microscope. Each muscle was weighed to a precision of 0.1 mg on a balance (Pioneer, Ohaus). A panel of muscles was examined because muscles of different size, shape, proportion of the oxidative and glycolytic fibres, or pattern of activation may be affected by different genetic mechanisms. The soft tissues were removed from the tibia and bone length was measured to a precision of 0.01 mm with a digital caliper (Z22855, OWIM GmbH & Co).

#### *Apparent bone mineral content*

Mineral content of the tibia was measured with the Faxitron MX-20 scanner (Faxitron Bioptics LLC, AZ, USA) using methods adapted from (Bassett *et al.*, 2012). Three types of materials; 0.8 mm of aluminium, 1.0 mm of polystyrene and 0.8 mm of steel, were scanned together with the bones for calibration of the image. ImageJ (V1.48p, National Institutes of Health, USA) was used to quantify the apparent bone mineral content, appBMC, and the bone size. The appBMC was characterized by the mean, mode, median, minimum, maximum, standard deviation, skewness and kurtosis of the optical density of bone image. The bone area, perimeter, Feret’s diameter (longest distance between 2 points on the perimeter), and width and height of the bounding rectangle characterized the bone size.

### *Pre-processing of Phenotype Data*

Analysis of the phenotypic data was performed using the R statistical analysis software<sup>59</sup>. Outliers, defined as observations more than 3 standard deviations from the mean, were excluded. The effect of covariates such as sex and batch on quantitative phenotypes were assessed with analysis of variance (ANOVA) and those explaining more than 1% of the variance at  $P < 0.05$  were included in a multiple linear regression model from which residual measures were obtained. Batch, defined here as mice of the same age in each individual shipment, was treated as a random effect. All tests with covariates and models used to generate the residuals for genetic mapping are shown in Supplementary Table 1. We then quantile-normalised the residuals to minimize the effects of non-normality.

### *Sequencing*

Genomic DNA was extracted from tissue samples of 2,028 mice that began the pipeline using Nucleon BACC resin (Hologic) following the manufacturer's instructions. DNA was obtained from an additional 45 mice from the same population where no phenotypic measures were available producing a total of 2073 samples for analysis. Each individual DNA sample was then sonicated and barcoded with an in house unique 8-mer oligonucleotide<sup>60</sup>. Groups of 95 barcoded DNA samples were pooled and pair end 100bp sequenced on 1 lane Hi-Seq generating read groups of ~30 Gb sequence per lane/pool.

### *Alignment to mm10 reference and pre-processing of sequence data*

BWA version 0.5.6<sup>61</sup> was used to align the reads from each read group to the mouse mm10 reference genome. The BWA alignments were refined with Stampy v1.0.21<sup>62</sup> and converted into the bam format by samtools v0.1.18-dev<sup>63</sup>. Library PCR duplicates were

removed with samtools and sequence reads processed following the pipeline described<sup>11,13</sup>. All bam files were processed through the Indel Realignment and Base Quality Score Recalibration steps of the Genome Analysis Toolkit (GATK)<sup>8</sup> recommended Best Practices<sup>64</sup>. All pre-processing used GATK v2.4-9-g532efad. The option `-rf BadCigar` was applied to filter out reads that a) have hard/soft clips in the middle of the CIGAR string, b) start or end in deletions, c) fully hard/soft clipped, d) have consecutive INDELS in them. The option `-rf BadMate` was applied to filter out reads whose mate maps to a different contig. Previously discovered INDELS from all mouse strains in the Mouse Genome Project (MGP)<sup>11,65</sup> were used as intervals for Indel Realignment in addition to those discovered in the 2073 mice, and SNPs from the *Mus musculus domesticus* strains in MGP were used as known sites masked for Base Quality Score Recalibration.

#### *Variant calling from low coverage sequencing data*

Variant calling was then performed using all 2073 bam files with GATK's Unified Genotyper with thresholds `-stand_call_conf 30` and `-stand_emit_conf 30`, as well as options for building variant quality recalibration tables: `-A QualByDepth -A HaplotypeScore -A BaseQualityRankSumTest -A ReadPosRankSumTest -A MappingQualityRankSumTest -A RMSMappingQuality -A DepthOfCoverage -A FisherStrand -A HardyWeinberg -A HomopolymerRun`.

Raw vcf files from variant calling step for all chromosomes except chromosome Y were pooled together for variant quality score recalibration (VQSR) using GATK's VariantRecalibrator under SNP mode. Training, known and true sets for building the positive model are the SNPs which segregate among the classical laboratory strains of the Mouse Genomes Project<sup>11</sup> (2011 release REL-1211) on all chromosomes except chromosome Y. Transversion ratios (TsTv) and recalibration tables were generated at 14

sensitivities (100.0, 99.9, 99.0, 97.0, 95.0, 90.0, 85.0, 80.0, 75.0, 70.0, 65.0, 60.0, 55.0, 50.0) to training sets for runs of VQSR utilizing different sets of annotations. A final set of annotations for VQSR and sensitivities to known sites were chosen to maximize TsTv at both known and novel sites to reduce the rate of false positive calls. Sensitivity of 97% for known sites was selected for a total of 8,597,879 SNPs (6,430,809 known and 2,177,070 novel, TsTv of 2.13 at known sites and 1.56 at novel sites). We then further removed sites that were fixed alternative allele variants (hence non-polymorphic in our study) or were multi-allelic, leaving 7,073,398 (5,701,865 known, 1,371,533 novel, TsTv of 2.13 at known sites and 1.56 at novel sites) biallelic SNPs. The annotations used for VQSR were HaplotypeScore, BaseQualityRankSumTest, ReadPosRankSumTest, MappingQualityRankSumTest, RMSMappingQuality, DepthOfCoverage, FisherStrand, HardyWeinberg, HomopolymerRun.

We used the 7M biallelic SNPs in the mice cohort for imputation, using the method described below. To ensure quality of the imputed SNPs used for downstream genetic analysis, we first extracted those SNPs imputed with high certainty using IMPUTE2-style INFO scores. We observed from inspecting allele distributions that an INFO score greater than 0.4 indicated markers where the three genotype classes were clearly separable. Thus we included only sites that met this criterion. We also discarded sites where more than 10% of mice had maximum genotype probability smaller than 0.9, and on autosomal chromosomes we discarded sites where the P-value for violation of Hardy Weinberg equilibrium was smaller than  $10^{-6}$ . This resulted in a final set of 5.76M SNPs that we used for genetic mapping. Lastly, we used the most current release of the Sanger mouse genomes database (2016, REL-1505, comprising 36 genomes, almost twice the original number) to refine the set of novel SNPs. The number of novel sites

among the 5.76M dropped from 799,133 (13.8%) to 152,671 (2.6%) (Supplemental Table S3). However, the TsTv ratios for the novel SNPs remained little changed, at 1.74 and 1.73 respectively.

### *Imputation*

We developed a novel imputation algorithm, STITCH, described in a separate publication (Davies et al). This employed a hidden Markov model (HMM) that extended the population genetic methods of Li and Stephens<sup>66</sup>, and more specifically the fastPHASE algorithm of Scheet and Stephens<sup>67</sup>. We assume that the CFW population was founded with  $K$  unknown ancestral haplotypes and that the chromosomes of each sequenced CFW mice are mosaics of the founder haplotypes. After some experimentation with different values of  $K$  we found that  $K=4$  was optimal (ie the population was modeled as being founded from two individuals).

Simulating under the model (hidden ancestral states and sequencing reads) consists of: (i) choosing initial state probabilities ( $\pi_k$ ) from one of the  $k$  haplotypes (ii) choosing where to recombine between ancestral haplotypes assuming  $T=100$  of generations since the population's founding and a genetic distance between SNPs  $t$  and  $t + 1$  ( $\sigma_t$ ), (iii) choosing the ancestry within each segment with respect to the frequencies of each founder haplotype at that location ( $\alpha_{t,k}$ ), and (iv) sampling read locations, base qualities, underlying unobserved bases and observed sequenced bases, based on the relative probability that ancestral haplotype  $k$  emits a reference or ancestral base at SNP  $t$  ( $\theta_{t,k}$ ). Together, these represent the parameters of the model  $\lambda = (\pi, \sigma, \alpha, \theta)$ .

To generate the probabilistic genotype of an individual CFW outbred mouse, we first calculate the probability of observing a given sequencing read given membership in ancestral haplotype  $k$ , as follows. We first removed SNPs with low base quality ( $<17$ ) and SNPs in reads with low mapping quality ( $<17$ ). For an individual read  $R_r$  indexed by  $r$ , let  $J_r$  be the number of SNPs in the read and  $P(s_{r,j}|g_i = i) = \phi_{r,j}^i$  the base-quality scaled emission probability of sequencing read  $s_{r,j}$  given true underlying genotype  $i$ . Let SNP  $j$  in read  $R_r$  correspond to SNP  $u_{r,j}$ . We assume the probability of a recombination within a read is low, so we assign each read as having been emitted from a central SNP  $t = c_r$ . Therefore, the probability of read  $R_r$  given it came from ancestral haplotype  $k$  is

$$P(R_r|q_t = k) = \prod_{j=1}^{J_r} \left( \theta_{u_{r,j},k} \phi_{r,j}^1 + (1 - \theta_{u_{r,j},k}) \phi_{r,j}^0 \right)$$

and the probability of observing all reads at SNP  $t$  in a diploid sample given diploid hidden state at SNP  $t$  of  $q_t = (k_1, k_2)$  is

$$P(O_t|q_t = (k_1, k_2)) = \prod_{r:c_r=t} \left( \frac{1}{2} P(R_r|q_t = k_1) + \frac{1}{2} P(R_r|q_t = k_2) \right)$$

The full chromosome diploid probability is then calculated using the initial, recombination and transition probabilities in the normal manner.

We ran the method for 40 Expectation-Maximisation (EM) iterations, where in each iteration, during the expectation step, state probabilities are calculated for each mouse using the current parameters of the model, while in the maximization step, new initial, transition, recombination and emission parameters are estimated based on state probabilities. Upon completion, haplotype and genotype probabilities, as well as dosages,

are calculated. For example, the dosage of the number of Alt alleles is  $1 * P(G = (\text{Ref}, \text{Alt}) | O, \lambda) + 2 * P(G = (\text{Alt}, \text{Alt}) | O, \lambda)$  for a given mouse and SNP site.

### *Selection of tagging SNPs*

We then identified a subset of 359,559 (353,697 autosomal) tagging SNPs with MAF > 0.1% and LD  $r^2 < 0.98$ . Genotypes at these sites were called based on maximum genotype probability from imputation; genotypes were only called based on maximum genotype probabilities of higher than 0.9, mice with maximum genotype probability of smaller than 0.9 at a particular site would have a missing genotype at the site.

### *Sample selection based on estimation of Identity by Descent (IBD) between samples*

Pairwise Identity by Descent (IBD) was estimated by calculation of pairwise Identity by State (IBS) using PLINK (v1.07) at the tagging SNPs located on the autosomal chromosomes. Mice were excluded from further analysis if they had estimated PIHAT of higher than 0.5 with at least one other mice, or percentage IBS=1 of higher than 0.75 with at least one other mice, or percentage of IBS=0 of smaller than 0.25 with at least one other mice. 135 mice were excluded by the above criteria.

### *Sample Selection based on Principal Component Analysis (PCA)*

Linkage Disequilibrium Adjusted Kinship (LDAK, version 5.9) <sup>68</sup> was used to estimate local linkage disequilibrium (LD) by calculation of local pairwise correlations between SNPs and generating weightings of each SNP in the calculation of a genetic relatedness matrix (GRM) adjusted for local LD. The GRM was generated using hard-called genotypes at the tagging SNPs of MAF > 5% from all autosomes. Principal component analysis (PCA) was performed on the GRM to derive the top 20 principal components (PCs). PC2

separates out four mice from the rest; these four mice were excluded from further analysis.

### *Estimation of whole-genome SNP-based heritability*

LDAK (version 5.9) was used to generate a new GRM using hard-called genotypes of MAF > 5% at the same tagging SNPs in mice remaining in the analysis. Restricted maximum likelihood (REML) was used to estimate  $h^2$  of each of the 200 phenotypes measured.

### *QTL mapping*

We mapped quantitative trait loci (QTLs) at the tagging SNPs using purpose-written software in R. For each phenotype  $k$ , we used the quantile-normalised residuals  $\mathbf{y}_k$  for QTL mapping and heritability analysis. Although we found little evidence of unequal degrees of relatedness between the CFW mice, as a precaution we used mixed models to control for cryptic relatedness and to avoid false positive QTL calls. We first used the imputed dosages of the tagging SNPs on the autosomal chromosomes to compute genome wide kinship matrices ( $K$ ). Thus, if  $a_{ip}$  is the imputed reference allele dosage of SNP  $p$  in individual  $i$  then the genetic relationship  $K_{ij}$  between individuals  $i, j$  is defined to be the Pearson correlation coefficient of the vectors  $a_{ip}, a_{jp}$  across all autosomal tagging SNPs  $p$ . The  $i, j$  'th element of the population-wide genetic relationship matrix  $K$  is  $K_{ij}$ . We also computed leave-one-out kinship matrices  $K_c$  for each chromosome  $c$ , using all tagging SNPs not on chromosome  $c$ .

We modified the standard mixed model formulation for mapping QTLs by computing separate mixed models for each chromosome, in order to ameliorate the reduction in

statistical significance of a locus caused by the same information being present in the kinship matrix. To test association between the phenotype  $k$  and tagging SNP  $p$  resident on chromosome  $c$ , we estimated the phenotypic covariance matrix  $V_{kc} = \sigma_{gkc}^2 K_c + \sigma_{ekc}^2 I$  where the genetic and environmental variance components  $\sigma_{gkc}^2, \sigma_{ekc}^2$  are estimated as above, and factorized it into its square root using the eigen-decomposition

$$V_{kc} = E'_{kc} \Lambda_{kc} E_{kc} = (E'_{kc} \Lambda_{kc}^{1/2} E_{kc})^2 = A_{kc}^2$$

where  $E_{kc}$  is the orthogonal matrix of eigenvectors and  $\Lambda_{kc}$  the diagonal matrix of eigenvalues of  $V_{kc}$ . Then we fitted the transformed mixed model

$$\mathbf{z}_{kc} = A_{kc}^{-1} \mathbf{y}_k = \mu + \alpha(A_{kc}^{-1} \mathbf{a}_p) + \mathbf{e}$$

where  $\mu, \alpha$  are parameters to be estimated, and the error vector  $\mathbf{e}$  is uncorrelated so the model can be fit efficiently by computing the correlation coefficient of  $\mathbf{z}_{kc}, A_{kc}^{-1} \mathbf{a}_p$ .

Nominal statistical significance at a locus was measured as the logP (the negative log<sub>10</sub> of the P-value of the ANOVA comparing the fit of the allele model to the null model). We defined a candidate QTL as any locus such that the logP was at a local maximum compared to the tests at neighbouring loci, and no other locus within 3Mb had a larger logP.

We estimated separate genome-wide thresholds for each phenotype, aiming to control the per-phenotype false discovery rate (FDR). We made  $Q = 100$  permutations of each transformed phenotype vector  $\mathbf{z}_{kc}$ , keeping the transformed allele dosages fixed, and refitted the model. This is efficient because most of the computational effort in fitting a mixed model is reusable when fitting the permuted phenotypes. We found candidate

QTLs in the permuted data in the same way and estimated the per-phenotype FDR of a QTL as

$$FDR_k(x) = \frac{P_k(x)}{QN_k(x)}$$

where  $N_k(x)$ ,  $P_k(x)$  are the numbers of QTLs with  $\log P \geq x$  observed for phenotype  $k$  in the unpermuted and permuted data respectively, and  $Q = 100$  is the number of permutations.

### *Fine mapping*

Once a QTL had been mapped using the tagging SNPs and exceeded the FDR threshold, association was re-calculated with all imputed SNPs (from the 5.7M set) in a 20Mb window around the peak using the same mixed model.

### *Confidence Interval Estimation*

Confidence intervals were estimated by simulation. First, at each QTL, a residual phenotype was constructed by removing the effect of the top SNP at the QTL from the phenotype vector used in the QTL mapping above. This ablated the QTL whilst maintaining genetic contributions from elsewhere in the genome. Next, 1000 SNPs were selected at random, subject to the constraint that they were within 2.5Mb of the top SNP and were polymorphic in the subset of individuals phenotyped for the trait (where the 95% interval estimate was 2.0 Mb or greater, we repeated the analysis using SNPs up to 10Mb from the top SNP). A causal variant was simulated at the SNP, with effect size matching that of the top SNP, taking account of the allele frequency, and its trait value added to the residual phenotype. A local scan of the region using the same mixed model but the simulated phenotype was performed and the location and  $\log P$  of the top SNP

recorded. Across the 1000 simulations, we estimated the distribution of the drop  $\Delta$  in  $\log P$  between the simulated top SNP and the simulated causal SNP (this was zero when the top and causal SNPs coincided). We used the fraction of simulations  $f(\Delta)$  within  $\Delta$  to determine confidence intervals for the original phenotype data. Thus we identified the range of SNPs within 2.5Mb of the top SNP and with a  $\log P$  drop less than  $\Delta$  to define the  $100f(\Delta)\%$  confidence interval for the QTL. We did this using both the tagging SNPs and the fine-mapping SNPs.

### *Power Calculation*

Since we applied an FDR approach to call QTLs we did not require a  $\log P$  threshold that would be required in order to determine power. However, in order to estimate power and the effects of sample size and effect size, we determined approximate genome-wide thresholds based on permutations of the mixed-model transformed phenotypes  $z = A^{-1}y$  keeping the genotypes fixed in order to preserve LD structure. For each of the 200 phenotypes, we performed 100 permutations and computed the genome-wide maximum  $\log P$  across the 359,559 tagging SNPs in order to define genome-wide thresholds  $T(p)$  at  $p = 0.5, 0.1, 0.05$  levels of significance (e.g. the threshold  $T(p)$  is such that in a fraction  $p$  of simulations the genomewide maximum  $\log P$  exceeds  $T(p)$ ). Thresholds vary slightly between phenotypes, so we used the thresholds obtained by pooling all 20,000 simulations to estimate power for sample sizes  $N = 1000, 1732, 2000, 4000$  and apparent effect sizes  $v = 0.01, 0.016, 0.02$ . ( $N = 1732$  and  $v = 0.016$  are the median sample size and effect size in the current study). Power  $\pi(N, v, T)$  to detect a QTL with effect size  $v$  and sample size  $N$  at genome-wide  $\log P$  threshold  $T$ , was computed as  $\pi(N, v, T) = \Pr(X > w(T) | X \sim \chi_{1, Nv}^2)$  where  $\chi_{1, Nv}^2$  is the noncentral chi-square distribution on 1df with noncentrality parameter  $Nv$ , and  $w(T)$  is the quantile of a

standard chi-squared distribution corresponding to  $\log P T$ , ie  $\Pr(X > w(T) | X \sim \chi_{1,0}^2) = 10^{-T}$ .

#### *Data availability*

Results from this project and the data used for analysis are maintained in an open access database, available at <http://outbredmice.org>. Sequencing reads are obtainable from the [European Nucleotide Archive: http://www.ebi.ac.uk/ena/data/view/ERP001040](http://www.ebi.ac.uk/ena/data/view/ERP001040).

#### *Software availability*

Custom R code for QTL mapping, written specifically for this project, is available from Richard Mott ([r.mott@ucl.ac.uk](mailto:r.mott@ucl.ac.uk)). STITCH is available from Robert Davies ([robertwilliamdavies@gmail.com](mailto:robertwilliamdavies@gmail.com))

## References

1. Flint, J. & Eskin, E. Genome-wide association studies in mice. *Nat Rev Genet* **13**, 807-17 (2012).
2. Visscher, P.M., Brown, M.A., McCarthy, M.I. & Yang, J. Five years of GWAS discovery. *Am J Hum Genet* **90**, 7-24 (2012).
3. Atwell, S. *et al.* Genome-wide association study of 107 phenotypes in Arabidopsis thaliana inbred lines. *Nature* **465**, 627-31 (2010).
4. Huang, X. *et al.* Genome-wide association studies of 14 agronomic traits in rice landraces. *Nat Genet* **42**, 961-7 (2010).
5. Yalcin, B. *et al.* Commercially available outbred mice for genome-wide association studies. *PLoS Genet* **6**, e1001085 (2010).
6. 1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing. *Nature* **467**, 1061-73 (2010).
7. Marchini, J. & Howie, B. Genotype imputation for genome-wide association studies. *Nat Rev Genet* **11**, 499-511 (2010).
8. McKenna, A. *et al.* The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res* **20**, 1297-303 (2010).
9. Yang, H. *et al.* A customized and versatile high-density genotyping array for the mouse. *Nat Methods* **6**, 663-6 (2009).
10. Rat Genome, S. *et al.* Combined sequence-based and genetic mapping analysis of complex traits in outbred rats. *Nat Genet* **45**, 767-75 (2013).
11. Keane, T.M. *et al.* Mouse genomic variation and its effect on phenotypes and gene regulation. *Nature* **477**, 289-94 (2011).
12. Bennett, B.J. *et al.* A high-resolution association mapping panel for the dissection of complex traits in mice. *Genome Res* **20**, 281-90 (2010).
13. Wong, K. *et al.* Sequencing and characterization of the FVB/NJ mouse genome. *Genome Biol* **13**, R72 (2012).
14. Listgarten, J. *et al.* Improved linear mixed models for genome-wide association studies. *Nat Methods* **9**, 525-6 (2012).
15. Yang, J., Zaitlen, N.A., Goddard, M.E., Visscher, P.M. & Price, A.L. Advantages and pitfalls in the application of mixed-model association methods. *Nat Genet* **46**, 100-6 (2014).
16. Cheng, R., Parker, C.C., Abney, M. & Palmer, A.A. Practical considerations regarding the use of genotype and pedigree data to model relatedness in the context of genome-wide association studies. *G3 (Bethesda)* **3**, 1861-7 (2013).
17. Manichaikul, A., Dupuis, J., Sen, S. & Broman, K.W. Poor performance of bootstrap confidence intervals for the location of a quantitative trait locus. *Genetics* **174**, 481-9 (2006).
18. Taylor, M., Valdar, W., Kumar, A., Flint, J. & Mott, R. Management, presentation and interpretation of genome scans using GSCANDB. *Bioinformatics* **23**, 1545-9 (2007).
19. Weng, W. & Breslow, J.L. Dramatically decreased high density lipoprotein cholesterol, increased remnant clearance, and insulin hypersensitivity in apolipoprotein A-II knockout mice suggest a complex role for apolipoprotein A-II in atherosclerosis susceptibility. *Proc Natl Acad Sci U S A* **93**, 14788-94 (1996).

20. Coury, F. *et al.* SLC4A2-mediated Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange activity is essential for calpain-dependent regulation of the actin cytoskeleton in osteoclasts. *Proc Natl Acad Sci U S A* **110**, 2163-8 (2013).
21. Bladt, F., Riethmacher, D., Isenmann, S., Aguzzi, A. & Birchmeier, C. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. *Nature* **376**, 768-71 (1995).
22. Dietrich, S. *et al.* The role of SF/HGF and c-Met in the development of skeletal muscle. *Development* **126**, 1621-9 (1999).
23. Webster, M.T. & Fan, C.M. c-MET regulates myoblast motility and myocyte fusion during adult skeletal muscle regeneration. *PLoS One* **8**, e81757 (2013).
24. Zhang, X.K. *et al.* The transcription factor Fli-1 modulates marginal zone and follicular B cell development in mice. *J Immunol* **181**, 1644-54 (2008).
25. Cryan, J.F. *et al.* Antidepressant and anxiolytic-like effects in mice lacking the group III metabotropic glutamate receptor mGluR7. *Eur J Neurosci* **17**, 2409-17 (2003).
26. Duprez, D.M., Coltey, M., Amthor, H., Brickell, P.M. & Tickle, C. Bone morphogenetic protein-2 (BMP-2) inhibits muscle development and promotes cartilage formation in chick limb bud cultures. *Dev Biol* **174**, 448-52 (1996).
27. Dougherty, S.E. *et al.* Mice lacking the transcriptional coactivator PGC-1alpha exhibit alterations in inhibitory synaptic transmission in the motor cortex. *Neuroscience* **271**, 137-48 (2014).
28. Nakura, A., Higuchi, C., Yoshida, K. & Yoshikawa, H. PKCalpha suppresses osteoblastic differentiation. *Bone* **48**, 476-84 (2011).
29. Galea, G.L. *et al.* Protein kinase Calpha (PKCalpha) regulates bone architecture and osteoblast activity. *J Biol Chem* **289**, 25509-22 (2014).
30. Sanyal, M. *et al.* B-cell development fails in the absence of the Pbx1 proto-oncogene. *Blood* **109**, 4191-9 (2007).
31. Kennedy, M.K. *et al.* Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. *J Exp Med* **191**, 771-80 (2000).
32. Cannarile, M.A. *et al.* Transcriptional regulator Id2 mediates CD8<sup>+</sup> T cell immunity. *Nat Immunol* **7**, 1317-25 (2006).
33. Chen, Z., Cooper, B., Kalla, S., Varoqueaux, F. & Young, S.M., Jr. The Munc13 proteins differentially regulate readily releasable pool dynamics and calcium-dependent recovery at a central synapse. *J Neurosci* **33**, 8336-51 (2013).
34. Reddy, S.Y. *et al.* Sleep quality, BDNF genotype and gene expression in individuals with chronic abdominal pain. *BMC Med Genomics* **7**, 61 (2014).
35. Melcher, T. *et al.* RED2, a brain-specific member of the RNA-specific adenosine deaminase family. *J Biol Chem* **271**, 31795-8 (1996).
36. Mittaz, L., Antonarakis, S.E., Higuchi, M. & Scott, H.S. Localization of a novel human RNA-editing deaminase (hRED2 or ADARB2) to chromosome 10p15. *Hum Genet* **100**, 398-400 (1997).
37. Collier, F.M. *et al.* Identification and characterization of a lymphocytic Rho-GTPase effector: rhotekin-2. *Biochem Biophys Res Commun* **324**, 1360-9 (2004).
38. Ramos-Quiroga, J.A. *et al.* Genome-wide copy number variation analysis in adult attention-deficit and hyperactivity disorder. *J Psychiatr Res* **49**, 60-7 (2014).
39. Zaffaroni, D. *et al.* Met proto-oncogene juxtamembrane rare variations in mouse and humans: differential effects of Arg and Cys alleles on mouse lung tumorigenesis. *Oncogene* **24**, 1084-90 (2005).

40. Ma, P.C. *et al.* c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. *Cancer Res* **63**, 6272-81 (2003).
41. Bloemberg, D. & Quadriatero, J. Rapid determination of myosin heavy chain expression in rat, mouse, and human skeletal muscle using multicolor immunofluorescence analysis. *PLoS One* **7**, e35273 (2012).
42. Peirce, J.L., Lu, L., Gu, J., Silver, L.M. & Williams, R.W. A new set of BXD recombinant inbred lines from advanced intercross populations in mice. *BMC Genet* **5**, 7 (2004).
43. Churchill, G.A. *et al.* The Collaborative Cross, a community resource for the genetic analysis of complex traits. *Nat Genet* **36**, 1133-7 (2004).
44. Svenson, K.L. *et al.* High-resolution genetic mapping using the Mouse Diversity outbred population. *Genetics* **190**, 437-47 (2012).
45. Valdar, W. *et al.* Genome-wide genetic association of complex traits in heterogeneous stock mice. *Nat Genet* **38**, 879-87 (2006).
46. Pallares, L.F. *et al.* Mapping of Craniofacial Traits in Outbred Mice Identifies Major Developmental Genes Involved in Shape Determination. *PLoS Genet* **11**, e1005607 (2015).
47. Varban, M.L. *et al.* Targeted mutation reveals a central role for SR-BI in hepatic selective uptake of high density lipoprotein cholesterol. *Proc Natl Acad Sci U S A* **95**, 4619-24 (1998).
48. Munoz-Bravo, J.L. *et al.* GDNF is required for neural colonization of the pancreas. *Development* **140**, 3669-79 (2013).
49. Solberg, L.C. *et al.* A protocol for high-throughput phenotyping, suitable for quantitative trait analysis in mice. *Mamm Genome* **17**, 129-46 (2006).
50. Yee, B.K., Chang, T., Pietropaolo, S. & Feldon, J. The expression of prepulse inhibition of the acoustic startle reflex as a function of three pulse stimulus intensities, three prepulse stimulus intensities, and three levels of startle responsiveness in C57BL6/J mice. *Behav Brain Res* **163**, 265-76 (2005).
51. Yee, B.K. & Feldon, J. Distinct forms of prepulse inhibition disruption distinguishable by the associated changes in prepulse-elicited reaction. *Behav Brain Res* **204**, 387-95 (2009).
52. Line, S.J. *et al.* Reduced sensitivity to both positive and negative reinforcement in mice over-expressing the 5-hydroxytryptamine transporter. *Eur J Neurosci* **40**, 3735-45 (2014).
53. Porsolt, R.D., Le Pichon, M. & Jalfre, M. Depression: a new animal model sensitive to antidepressant treatments. *Nature* **266**, 730-2 (1977).
54. Mang, G.M. *et al.* Evaluation of a piezoelectric system as an alternative to electroencephalogram/ electromyogram recordings in mouse sleep studies. *Sleep* **37**, 1383-92 (2014).
55. Kema, I.P. *et al.* High performance liquid chromatographic profiling of tryptophan and related indoles in body fluids and tissues of carcinoid patients. *Clin Chim Acta* **221**, 143-58 (1993).
56. Balmus, G. *et al.* A high-throughput in vivo micronucleus assay for genome instability screening in mice. *Nat Protoc* **10**, 205-15 (2015).
57. Huang, G.J. *et al.* A genetic and functional relationship between T cells and cellular proliferation in the adult hippocampus. *PLoS Biol* **8**, e1000561 (2010).
58. Clark, L.D., Clark, R.K. & Heber-Katz, E. A new murine model for mammalian wound repair and regeneration. *Clin Immunol Immunopathol* **88**, 35-45 (1998).

59. R Core Team. R: A Language and Environment for Statistical Computing. 3.1.3 edn (R Foundation for Statistical Computing, Vienna, Austria, 2015).
60. Lamble, S. *et al.* Improved workflows for high throughput library preparation using the transposome-based Nextera system. *BMC Biotechnol* **13**, 104 (2013).
61. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* **25**, 1754-60 (2009).
62. Lunter, G. & Goodson, M. Stampy: a statistical algorithm for sensitive and fast mapping of Illumina sequence reads. *Genome Res* **21**, 936-9 (2011).
63. Li, H. *et al.* The Sequence Alignment/Map format and SAMtools. *Bioinformatics* **25**, 2078-9 (2009).
64. DePristo, M.A. *et al.* A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nat Genet* **43**, 491-8 (2011).
65. Yalcin, B. *et al.* Sequence-based characterization of structural variation in the mouse genome. *Nature* **477**, 326-9 (2011).
66. Li, N. & Stephens, M. Modeling linkage disequilibrium and identifying recombination hotspots using single-nucleotide polymorphism data. *Genetics* **165**, 2213-33 (2003).
67. Scheet, P. & Stephens, M. A fast and flexible statistical model for large-scale population genotype data: applications to inferring missing genotypes and haplotypic phase. *Am J Hum Genet* **78**, 629-44 (2006).
68. Speed, D., Hemani, G., Johnson, M.R. & Balding, D.J. Improved heritability estimation from genome-wide SNPs. *Am J Hum Genet* **91**, 1011-21 (2012).
69. Pruim, R.J. *et al.* LocusZoom: regional visualization of genome-wide association scan results. *Bioinformatics* **26**, 2336-7 (2010).

## Tables

**Table 1. QTLs mapping to a single gene**

Phenotype	Chr.	Position (Mb)	-logP	Gene	References
<i>Knock-out mouse recapitulates the phenotype</i>					
Weight of soleus muscle (g)	6	17.5	16.2	<i>Met</i>	21-23
Total distance travelled in Elevated Plus Maze (cm)					25
CD45+/CD3-/CD19+ cells (%)	6	110.2	5.6	<i>Grm7</i>	
	9	32.6	5.8	<i>Fli1</i>	24
<i>Association supported by literature</i>					
CD45+/CD3-/DX5+ cells (%)	1	168.2	4.7	<i>Pbx1</i>	30
Wound healing	2	134.2	5.5	<i>Bmp2</i>	26
Number of long (>1min) sleep episodes	5	51.8	6.8	<i>Ppargc1a</i>	27
Ratio of CD3+/CD4+ to CD3+/CD8+ cells	8	82.4	8.7	<i>Il15</i>	31
Bone mineral content	11	108.2	4.6	<i>Prkca</i>	28,29
CD3+/CD8+ cells (%)	12	25.5	5.4	<i>Id2</i>	32
<i>No previous evidence</i>					
Length of tibia (mm)	5	51.7	4.5	<i>Ppargc1a</i>	
Startle pulse reactivity	6	17.5	6.7	<i>Met</i>	
Calcium (mmol/l)	6	17.5	8.3	<i>Met</i>	
Total Cholesterol (mmol/l)	6	17.5	6.1	<i>Met</i>	
Total Protein (g/l)	6	17.5	27.7	<i>Met</i>	
CD45+/CD3-/CD19+ cells (%)	7	72.2	6.2	<i>Mctp2</i>	
Number of long (>1min) sleep episodes	9	73.8	5.5	<i>Unc13c</i>	
Startle pulse reactivity	10	68.0	8.0	<i>Rtkn2</i>	
Weight of tibialis anterior muscle (g)	11	17.6	6.3	<i>Etaa1</i>	
Length of tibia (mm)	12	83.6	7.1	<i>Zfyve1</i>	
Basal activity	13	7.3	10.6	<i>Adarb2</i>	
Respiratory rate during Hypoxic Ventilatory Decline	13	118.0	5.9	<i>Hcn1</i>	
Total distance travelled in Elevated Plus Maze (cm)	14	82.1	6.2	<i>Pcdh17</i>	
Measure of the size of tibia	15	26.6	5.3	<i>Fbxl7</i>	
Percentage of Eosinophils (%)	17	70.4	5.2	<i>Dlgap1</i>	
Percentage of Eosinophils (%)	X	155.6	6.0	<i>Ptchd1</i>	

## Figure Legends

### Figure 1

Sequence diversity of the CFW population. **(a)** Distribution of heterozygosity in 100kbp windows genome-wide. **(b)** Histogram of genome-wide heterozygosity. **(c)** Example of novel and total SNP density for a region of chromosome 19. Results are representative of those seen genome-wide. **(d)** Minor allele frequency (MAF) density for population of wild Indian (n=10, 44.9 M whole genome sequencing SNPs), CFW mice (n=2,073, 5.7M imputed SNPs) and HS mice (n=1,904, 11K SNPs from a genotyping array). Known CFW variation refers to those variants also segregating among 14 sequenced classical inbred strains. **(e)** The extent of linkage disequilibrium in CFW and HS mice. Values are mean  $r^2$  between all pairs of SNPs binned by distance to the kbp.

### Figure 2

Properties of QTLs. Frequency distribution of **(a)** the size and **(b)** the number of genes present in the 95% confidence intervals (CI) in 255 QTLs, **(c)** The sum of variance explained by the QTLs plotted against heritability in 92 measures where heritability could be estimated and at least one QTL was detected. Colour of dots indicates the type of measure: behaviour, physiological (body weight, respiratory, electrocardiography) or tissue (any measure obtained after dissection)

### Figure 3

Summary Manhattan plot. Genome-wide representation of all unique QTLs (n=156, FDR<5%) identified in this study. Light and dark grey dots show association from the 92 measures where at least one QTL was detected at the tagging SNPs positions (n=359,559). Most significant SNPs at each QTL are marked with a colour dot, depending on the type of measure. Y-axis shows  $-\log_{10}(P)$  of the imputed allele dosages with tested measures and is truncated at  $-\log_{10}(P)=32$ . The position of the 2 strongest QTLs with  $-\log_{10}(P)$  values of 133 (chr4) and 76 (chr17) is marked by triangles.

### Figure 4

Single-gene resolution mapping at 4 loci using the entire set of SNPs (7.1 M). **(a)** Weight of soleus muscle on chromosome 6 (n=1832), **(b)** Measure of the number of long sleep episodes on chromosome 9 (n=1577), **(c)** Ratio of CD3+/CD4+ to CD3+/CD8+ cells on chromosome 8 (n=1324) and **(d)** Intensity of reaction to startle on chromosome 10 (n=1740). The plots were drawn using LocusZoom <sup>69</sup>. Strongest associated SNP is marked with a purple diamond, the other SNPs that passed post-imputation quality control (IMPUTE2-style INFO scores > 0.4 and HWE  $r^2 > 1e^{-6}$ ;) are coloured following LD  $r^2$  with strongest SNP. The grey dots represent SNPs that failed post-imputation QC and therefore were not used for the analysis.